Reviva Pharmaceuticals (RVPH) Stock Forecast, Price Target & Predictions
RVPH Stock Forecast
Reviva Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RVPH Analyst Ratings
According to 1 Wall Street analysts, Reviva Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RVPH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 24, 2022 | H.C. Wainwright | - | Buy | Initialise |
Reviva Pharmaceuticals's last stock rating was published by H.C. Wainwright on Jun 11, 2024. The company gave RVPH a "Buy" rating, the same as its previous rate.
Reviva Pharmaceuticals Financial Forecast
Reviva Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 4 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Reviva Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RVPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Reviva Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 4 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-10.61M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict RVPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Reviva Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Reviva Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 4 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-10.49M |
| Avg Forecast | $-5.85M | $-5.77M | $-6.09M | $-6.01M | $-5.58M | $-5.58M | $-7.26M | $-9.05M | $-7.87M | $-8.57M |
| High Forecast | $-5.85M | $-5.77M | $-6.09M | $-6.01M | $-5.58M | $-5.09M | $-7.26M | $-9.05M | $-5.34M | $-8.57M |
| Low Forecast | $-5.85M | $-5.77M | $-6.09M | $-6.01M | $-5.58M | $-6.06M | $-7.26M | $-9.05M | $-10.40M | $-8.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.22% |
Reviva Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Reviva Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 4 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $1.99M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Reviva Pharmaceuticals's average Quarter SG&A projection for Dec 23 is -, based on 4 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RVPH last annual SG&A of $1.99M (Sep 23).
Reviva Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 4 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.44 |
| Avg Forecast | $-0.24 | $-0.24 | $-0.25 | $-0.25 | $-0.23 | $-0.23 | $-0.30 | $-0.38 | $-0.33 | $-0.36 |
| High Forecast | $-0.24 | $-0.24 | $-0.25 | $-0.25 | $-0.23 | $-0.21 | $-0.30 | $-0.38 | $-0.22 | $-0.36 |
| Low Forecast | $-0.24 | $-0.24 | $-0.25 | $-0.25 | $-0.23 | $-0.25 | $-0.30 | $-0.38 | $-0.43 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.23% |
According to undefined Wall Street analysts, Reviva Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVPH previous annual EPS of $NaN (undefined).
Reviva Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| ATHA | Athira Pharma | $0.53 | $18.00 | 3296.23% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| SLS | SELLAS Life Sciences Group | $1.32 | $7.00 | 430.30% | Buy |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| EYPT | EyePoint Pharmaceuticals | $9.10 | $30.00 | 229.67% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.32 | $26.57 | 62.81% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
RVPH Forecast FAQ
Is Reviva Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Reviva Pharmaceuticals (RVPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RVPH's total ratings.
What are Reviva Pharmaceuticals's analysts' financial forecasts?
Reviva Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-27.463M (high $-26.978M, low $-27.947M), average SG&A $0 (high $0, low $0), and average EPS is $-1.143 (high $-1.123, low $-1.163). RVPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-23.713M (high $-23.713M, low $-23.713M), average SG&A $0 (high $0, low $0), and average EPS is $-0.987 (high $-0.987, low $-0.987).